Tokyo, Oct. 1 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059235) titled 'Combined effect of intravitreal faricimab and direct photocoagulation for focal diabetic macular edema' on Oct. 1.
Study Type:
Observational
Primary Sponsor:
Institute - university of Fukui Hospital
Condition:
Condition - diabetic macular edema
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - To clarify through a retrospective study which is more effective in localized diabetic macular edema: direct coagulation of residual edema after prior administration of faricimab, or administration of faricimab to residual edema after direct coagulation.
Basic objectives2 - Efficacy
Eligibility:
Age-lower limit - 20
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients with focal DME who required anti-VEGF treatment with faricimab and retinal photocoagulation at our hospital from June 1, 2022
Key exclusion criteria - 1. If the subject refuses to participate in the study
2. If the principal investigator (sub-investigator) otherwise determines that the subject is unsuitable as a subject
Target Size - 30
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2025 Year 09 Month 26 Day
Date of IRB - 2025 Year 09 Month 26 Day
Anticipated trial start date - 2025 Year 09 Month 26 Day
Last follow-up date - 2028 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000067753
Disclaimer: Curated by HT Syndication.
